Bexagliflozin: First Approval

被引：22
作者：
Hoy, Sheridan M. [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1007/s40265-023-01848-x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Bexagliflozin (BRENZAVVY (TM)) is an orally administered potent inhibitor of sodium-glucose transporter 2 (SGLT-2). It is being developed by TheracosBio for the treatment of type 2 diabetes (T2D) and essential hypertension, and in January 2023 it received its first approval in the USA for use as an adjunct to diet and exercise to improve glycaemic control in adults with T2D. Bexagliflozin is contraindicated in patients receiving dialysis and is not recommended in patients with type 1 diabetes or in those with an estimated glomerular filtration rate of < 30 mL/min/1.73 m(2). Bexagliflozin is undergoing clinical development for the treatment of essential hypertension in the USA. This article summarizes the milestones in the development of bexagliflozin leading to this first approval for the treatment of T2D.
引用
收藏
页码：447 / 453
页数：7
相关论文
共 15 条
[1]   Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus ana Stage 3a/3b CKD [J].
Allegretti, Andrew S. ;
Zhang, Wenbin ;
Zhou, Wenjiong ;
Thurber, Tara K. ;
Rigby, Scott P. ;
Bowman-Stroud, Cynthia ;
Trescoi, Carlos ;
Serusclat, Pierre ;
Freeman, Mason W. ;
Halvorsen, Yuan-Di C. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 74 (03) :328-337
[2]   SGLT2 inhibitors for diabetes: turning symptoms into therapy [J].
Diamant, Michaela ;
Morsink, Linde M. .
LANCET, 2013, 382 (9896) :917-918
[3]   A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults [J].
Halvorsen, Yuan-Di ;
Lock, John Paul ;
Frias, Juan P. ;
Tinahones, Francisco Jose ;
Dahl, Dominik ;
Conery, Annie L. ;
Freeman, Mason W. .
DIABETES OBESITY & METABOLISM, 2023, 25 (01) :293-301
[4]   A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes [J].
Halvorsen, Yuan-Di ;
Walford, Geoffrey ;
Thurber, Tara ;
Russell, Heidy ;
Massaro, Monica ;
Freeman, Mason W. .
DIABETES OBESITY & METABOLISM, 2020, 22 (04) :566-573
[5]   A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults [J].
Halvorsen, Yuan-Di ;
Lock, John P. ;
Zhou, Wenjiong ;
Zhu, Fang ;
Freeman, Mason W. .
DIABETES OBESITY & METABOLISM, 2019, 21 (10) :2248-2256
[6]   Cardiovascular and Glycemic Benefits of Bexagliflozin as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial [J].
Halvorsen, Yuan-Di C. ;
Lock, John P. ;
Freeman, Mason W. .
DIABETES, 2020, 69
[7]   A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes [J].
Halvorsen, Yuan-Di C. ;
Walford, Geoffrey A. ;
Massaro, Joseph ;
Aftring, Robert P. ;
Freeman, Mason W. .
DIABETES OBESITY & METABOLISM, 2019, 21 (11) :2496-2504
[8]   An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus [J].
Hsia, Daniel S. ;
Grove, Owen ;
Cefalu, William T. .
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2017, 24 (01) :73-79
[9]   The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial [J].
McMurray, John J. V. ;
Freeman, Mason W. ;
Massaro, Joe ;
Solomon, Scott ;
Lock, Paul ;
Riddle, Matthew C. ;
Halvorsen, Yuan-Di C. .
DIABETES, 2020, 69
[10]   The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis [J].
Peng, Yong ;
Qin, Di ;
Wang, Yudi ;
Xue, Lian ;
Qin, YaXuan ;
Xu, Xin .
FRONTIERS IN PHYSIOLOGY, 2023, 13
12